

Dott.ssa CAROLINA MARIA SASSU
Curriculum Vitae

<i>NAME</i>	CAROLINA MARIA SASSU
<i>Place and date of birth</i>	Rome, 28/04/89
<i>Nationality</i>	Italian
<i>Language</i>	Italian, English
<i>Current position</i>	Freelancer Fondazione Policlinico Universitario Agostino Gemelli, IRCCS of Rome
<i>Telephone number</i>	+39 393 56 91 077
<i>e-mail</i>	carolinamsassu@hotmail.it

EDUCATION

2009-2015 Medical School at “Sapienza” University of Rome, Policlinico Umberto I.

2013-2015 Integrative Programme: Percorso d’Eccellenza, “Sapienza” University of Rome, Policlinico Umberto I.

28/17/2015 Graduation Medicine (110/110 cum laude)

02/2016 Medical licence

10/2021 Specialization Gynecology and Obstetrics (70/70 cum laude)

11/2022-ongoing **PhD program “Experimental and Translational Medicine”**
Università Cattolica del Sacro Cuore, Rome, Italy.

WORK EXPERIENCE

2013-2016 Internship at Gynecology and Obstetrics, “Sapienza” University of Rome, Policlinico Umberto I.

11/2016-10/2021 Residency Programme, Gynecology and Obstetrics, “Sapienza” University of Rome, Policlinico Umberto I (Prof Benedetti Panici).

2017-2021 Subinvestigator of Multicenter Study “Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (BAROCCO).

2019-2021 Subinvestigator of Multicenter Study ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

2019-2021 Subinvestigator of Multicenter Study A Randomized Phase 3, Double-Blind Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK- 001/ENGOT-ov43)

2020 October, 19th-2021 April, 30th Internship in gynecologic oncology and ultrasound at First Medical Faculty of Charles University- General University Hospital in Prague (Prof. Fischerova)

2021 May-October Internship in gynecologic oncology and ultrasound at Fondazione Policlinico Universitario Agostino Gemelli, IRCCS of Rome

MEMBER OF SCIENTIFIC SOCIETIES

- International Ovarian Tumor Analysis “IOTA” member
- Multicentre Italian Trials in Ovarian cancer “MITO” group member
- Coordinator Multicentre Italian Trials in Ovarian cancer “MITO” Tumori Rari Group.

INTERNATIONAL PUBLICATIONS

1. Benedetti Panici P, Marchetti C, Musella A, Sabatucci I, Sassu C, Giannini A, Scione E, Di Donato V, Perniola G, Tomaiò F, Palaia I, Cognetti F, Muzii L. (2014). Phase II trial of weekly pegylated liposomal doxorubicin for treatment of advanced, persistent or recurrent ovarian carcinoma. In: IGCSM. International Journal of gynecological cancer, vol 24, p 123. Philadelphia, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS, ISSN 1048-891X, 2014.
2. Recine N, Palma E, Domenici L, Giorgini M, Imperiale L, Sassu C, Musella A, Marchetti C, Muzii L, Benedetti Panici P. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using *Lactobacillus rhamnosus* BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016 Jan;293(1):101-7. doi: 10.1007/s00404-015-3810-2. Epub 2015 Jul 5.
3. De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know. Cancer Treat Rev. 2017 Dec;61:1-5
4. Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P. Rucaparib: An emerging PARP inhibitor for treatment of recurrent ovarian cancer. Cancer Treat Rev. 2018 May;66:7-14.

5. Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. *Crit Rev Oncol Hematol*. 2018 Dec;132:111-115.
6. Tomao F, Di Pinto A, Sassu CM, Di Donato V, Muzii L, Petrella MC, Peccatori FA, Panici PB, Bardhi E. Fertility preservation in ovarian tumours. *Ecancermedalscience*. 2018 Dec 6;12:885. doi: 10.3332/ecancer.2018.885. eCollection 2018. Review.
7. Palaia I, Tomao F, Santangelo G, Di Pinto A, Sassu CM, Perniola G, Musella A, Di Donato V, Giacotti A, Benedetti Panici P. The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life. *Oncology*. 2019;97(5):306-310. doi: 10.1159/000501721. Epub 2019 Aug 22.
8. Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. *Cancer Treat Rev*. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Review.
9. Musella A, Santangelo G, Vertechy L, Di Pinto A, Sassu CM, Fischetti M, DiDonato V, Perniola G, Palaia I, Benedetti Panici P. Post-conization cervical stenosis treated with silicone catheter in microinvasive cervical cancer patient: A case report. *Int J Surg Case Rep*. 2020 Feb 6;67:95-97. ^[L]_[SEP]
10. Piccioni MG, Merlino L, Mariani M, Sassu C, Bracchi C, Tabacco S, Schiavi MC, Giannini A, Palaia I, Muzii L, Giacotti A, Monti M. Detection of twin reversed arterial perfusion sequence at the time of first ultrasound screening and its spontaneous resolution: A case report. *Gior It Ost Gin Vol XLI-n2*, Aprile-Giugno 2019
11. Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. *Onco Targets Ther*. 2020 Jun 26;13:6109-6129. doi: 10.2147/OTT.S205950.
12. Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research. *Cancer Manag Res*. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. PMID: 32765062; PMCID: PMC7369298.
13. Caruso G, Sassu CM, Tomao F, Di Donato V, Perniola G, Fischetti M, Benedetti Panici P, Palaia I. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions. *Crit Rev Oncol Hematol*. 2021 Apr 29;162:103344. doi: 10.1016/j.critrevonc.2021.103344
14. Di Donato V, Caruso G, Sassu CM, Santangelo G, Bogani G, Plotti F, Sorbi F, Perniola G, Palaia I, Terrin G, Angioli R, Benedetti Panici P, Muzii L. Fertility-sparing surgery for women with stage I cervical cancer of 4 cm or larger: a systematic review. *J Gynecol Oncol*. 2021 Nov;32(6):e83. doi: 10.3802/jgo.2021.32.e83.
15. Sassu CM, Palaia I, Boccia SM, Caruso G, Perniola G, Tomao F, Di Donato V, Musella A, Muzii L. Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer. *Int J Mol Sci*. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650.
16. Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G, Fagotti A. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. *Semin Cancer Biol*. 2021 Dec;77:144-166. doi: 10.1016/j.semcancer.2021.08.011.
17. Marchetti C, Ataseven B, Cassani C, Sassu CM, Congedo L, D'Indinosante M, Cappuccio S, Rhiem K, Hahnen E, Lucci Cordisco E, Arbustini E, Harter P, Minucci A, Scambia G, Fagotti A. Ovarian cancer

- onset across different *BRCA* mutation types: a view to a more tailored approach for *BRCA* mutated patients. *Int J Gynecol Cancer*. 2023 Feb 6;33(2):257-262. doi: 10.1136/ijgc-2022-003893.
18. Pozzati F, Sassu CM, Marini G, Mascilini F, Biscione A, Giannarelli D, Garganese G, Fragomeni SM, Scambia G, Testa AC, Moro F. Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer. *Ultrasound Obstet Gynecol*. 2023 Oct;62(4):594-602. doi: 10.1002/uog.26253. PMID: 37204769.
 19. Sassu CM, Marchetti C, Russo G, Minucci A, Boccia SM, Benato A, Nero C, Piermattei A, Mattogno PP, Giannarelli D, Ferrandina G, Olivi A, Fagotti A, Scambia G. Epithelial ovarian cancer and brain metastases: might the *BRCA* status, PARP inhibitor administration, and surgical treatment impact the survival? *Int J Gynecol Cancer*. 2024 Jan 5;34(1):88-98.
 20. Marchetti C, Ataseven B, Perrone AM, Cassani C, Fruscio R, Sassu CM, Apostol AI, Harter P, De Iaco P, Camnasio CA, Moubarak M, Giannarelli D, Scambia G, Fagotti A. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to *BRCA* mutational status. *Gynecol Oncol*. 2024 Aug;187:170-177.
 21. Bruno M, Apostol AI, Boccia SM, Sassu CM, Lardino S, Culcasi C, Lorusso D, Scambia G, Fagotti A, Marchetti C. Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients. *Int J Gynecol Cancer*. 2024 Jun 10:ijgc-2024-005363.
 22. Boccia SM, Sassu CM, Ergasti R, Vertechy L, Apostol AI, Palluzzi E, Fagotti A, Scambia G, Marchetti C. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? *Drug Des Devel Ther*. 2024 Jun 7;18:2021-2032.
 23. Giudice E, Salutari V, Sassu CM, Ghizzoni V, Carbone MV, Vertechy L, Fagotti A, Scambia G, Marchetti C. Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. *Expert Rev Anticancer Ther*. 2024 Aug;24(8):649-655.
 24. Marchetti C, Ergasti R, Capomacchia FM, Giannarelli D, Mastrantoni L, Pepe F, Apostol AI, Sassu CM, Nero C, Piermattei A, Zannoni GF, Troncone G, Colomban O, Russo G, Carrot A, Malapelle U, You B, Lorusso D, Scambia G, Fagotti A. Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery. *Gynecol Oncol*. 2025 Apr;195:16-25.
 25. Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri MT, Sassu CM, Camnasio CA, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia SM, Giannarelli D, Salutari V, Distefano M, Ferrandina MG, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D. Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to *BRCA1/2* mutation type and site: a multicenter real-world study. *ESMO Open*. 2025 Apr;10(4):104533.
 26. Ergasti R, Vertechy L, Ruscito I, Boccia SM, Congedo L, Sassu CM, Capomacchia FM, Costantini B, Distefano MG, Scambia G, Fagotti A, Marchetti C. Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study. *Eur J Surg Oncol*. 2025 Apr 4;51(8):110016.
 27. Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri MT, Sassu CM, Camnasio CA, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia SM, Giannarelli D, Salutari V, Distefano M, Ferrandina MG, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D. Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to *BRCA1/2* mutation type and site: a multicenter real-world study. *ESMO Open*. 2025 May 29;10(6):105289.
 28. Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri MT, Sassu CM, Camnasio CA, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia SM, Giannarelli D, Salutari V, Distefano M, Ferrandina MG, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D. Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to *BRCA1/2* mutation type and site: a multicenter real-world study: Not all *BRCA*

- mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response. *ESMO Open*. 2025 May 29;10(6):105299
29. Bruno M, De Paolis E, Minucci A, Piermattei A, Maneri G, Santoro A, Zannoni G, Scambia G, Sassu CM, Ciccarone F, Nero C, Marchetti C, Fagotti A. Comprehensive genomic profiling and clinicopathologic characterization of primary ovarian leiomyosarcoma. *Int J Gynecol Cancer*. 2025 Sep;35(9):102010.
 30. Giordano C, Sassu CM, Marchetti C, Guerri G, De Filippis A, Gulotta S, Marziali G, Russo G, Infante A, Mattogno PP, Olivi A, Fagotti A, Scambia G, Sala E, Gui B, Gaudino S. Brain metastases from ovarian cancer: neuroradiological profile and survival overview of neurosurgical cases. *J Neurooncol*. 2025 Dec;175(3):1285-1298.
 31. Vertechy L, Ergasti R, Chiamenti C, Arrigo D, Ruscito I, Rizzi A, Boccia SM, Sassu CM, Scambia G, Fagotti A, Marchetti C. Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis. *Int J Clin Oncol*. 2025 Sep;30(9):1873-1881.
 32. Imterat M, Bizzarri N, Stern S, Guidi G, Brandt B, Criscione M, Matan L, Arrigo D, Haran TK, Sassu C, Prus D, Bruno M, Perri T, Fagotti A. Gliomatosis peritonei with ovarian teratoma: an international multicenter case series. *Int J Gynecol Cancer*. 2025 Oct 17;36(1):102720.
 33. Apostol AI, Bruno M, Sassu CM, Boccia SM, Vertechy L, Russo G, Ruscito I, Capomacchia FM, Scambia G, Fagotti A, Marchetti C. Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy. *Int J Clin Oncol*. 2025 Nov 4.
 34. Boccia SM, Bruno M, Culcasi M, Guida F, Sassu CM, Vertechy L, Apostol AI, Russo G, Scambia G, Fagotti A, Marchetti C. Olaparib dose reduction in platinum-sensitive ovarian cancer recurrence: real-world data. *Int J Gynecol Cancer In press*.
 35. Trozzi R, Salvi M, Karimi M, Minucci A, Raspaglio G, De Donato M, Buttarelli M, Piermattei A, Vaccaro L, Grimaldi A, De Santis R, Massa M, Sillano F, Giacò L, Mastrantoni L, Iacobelli V, Camarda F, Cesana M, Duranti S, Sassu CM, Mattogno P, Fagotti A, Marchetti C, Scambia G, Nero C, Cacchiarelli D. Deciphering Brain Metastasis in Epithelial Ovarian Cancer: Multi-Omics Evidence and Potential Biomarkers. *Precision Oncology. In press*.

Roma, 21/11/2025
CAROLINA MARIA SASSU

